120 related articles for article (PubMed ID: 34605020)
21. Complications and hospital costs during hematopoietic stem cell transplantation for non-Hodgkin lymphoma in the United States.
Cho SK; McCombs J; Punwani N; Lam J
Leuk Lymphoma; 2019 Oct; 60(10):2464-2470. PubMed ID: 30848975
[TBL] [Abstract][Full Text] [Related]
22. Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study.
Bessou A; Colin X; De Nascimento J; Sopwith W; Ferrante S; Gorsh B; Gutierrez B; Sansbury L; Willson J; Sapra S; Paka P; Wang F
Eur J Health Econ; 2023 Apr; 24(3):321-333. PubMed ID: 35610398
[TBL] [Abstract][Full Text] [Related]
23. Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.
Yang X; Laliberté F; Germain G; Raut M; Duh MS; Sen SS; Lejeune D; Desai K; Armand P
Oncologist; 2021 May; 26(5):e817-e826. PubMed ID: 33616256
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma.
Lemieux C; Ahmad I; Bambace NM; Bernard L; Cohen S; Delisle JS; Fleury I; Kiss T; Mollica L; Roy DC; Sauvageau G; Roy J; Lachance S
Biol Blood Marrow Transplant; 2020 Jan; 26(1):157-161. PubMed ID: 31521818
[TBL] [Abstract][Full Text] [Related]
25. Patient-Reported Survivorship Care Practices and Late Effects After Treatment of Hodgkin and Non-Hodgkin Lymphoma.
Frick MA; Vachani CC; Hampshire MK; Bach C; Arnold-Korzeniowski K; Metz JM; Hill-Kayser CE
JCO Clin Cancer Inform; 2018 Dec; 2():1-10. PubMed ID: 30652594
[TBL] [Abstract][Full Text] [Related]
26. The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party.
Kyriakou C; Boumendil A; Finel H; Nn Norbert Schmitz ; Andersen NS; Blaise D; Chevallier P; Browne P; Malladi R; Niederwieser D; Pagliuca A; Kroschinsky F; Montoto S; Dreger P;
Biol Blood Marrow Transplant; 2019 Jan; 25(1):86-93. PubMed ID: 30219698
[TBL] [Abstract][Full Text] [Related]
27. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
[TBL] [Abstract][Full Text] [Related]
28. Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma.
Satwani P; Jin Z; Martin PL; Bhatia M; Garvin JH; George D; Chaudhury S; Talano J; Morris E; Harrison L; Sosna J; Peterson M; Militano O; Foley S; Kurtzberg J; Cairo MS
Leukemia; 2015 Feb; 29(2):448-55. PubMed ID: 24938649
[TBL] [Abstract][Full Text] [Related]
29. Are lifestyle behavioral factors associated with health-related quality of life in long-term survivors of non-Hodgkin lymphoma?
Spector DJ; Noonan D; Mayer DK; Benecha H; Zimmerman S; Smith SK
Cancer; 2015 Sep; 121(18):3343-51. PubMed ID: 26036473
[TBL] [Abstract][Full Text] [Related]
30. Response to hyperfractionated accelerated radiotherapy in chemotherapy-refractory non-Hodgkin lymphoma.
Kim DW; Lee G; Lee H; Mahal AR; Lam MB; Ng AK
Leuk Lymphoma; 2020 Jun; 61(6):1428-1434. PubMed ID: 32102580
[TBL] [Abstract][Full Text] [Related]
31. BEAM-Modified Conditioning Therapy with Cisplatin+Dexamethasone Instead of Carmustine Prior to Autologous Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Ron-Magaña AL; Fernandez-Vargas OE; Barrera-Chairez E; Ron-Guerrero CS; Bañuelos-Ávila AJ
Ann Transplant; 2019 Oct; 24():584-587. PubMed ID: 31636248
[TBL] [Abstract][Full Text] [Related]
32. Autologous hematopoietic stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study.
Hermet E; Cabrespine A; Guièze R; Garnier A; Tempescul A; Lenain P; Bouabdallah R; Vilque JP; Frayfer J; Bordessoule D; Sibon D; Janvier M; Caillot D; Biron P; Legros L; Choufi B; Drenou B; Gorin NC; Bilger K; Tamburini J; Soussain C; Brechignac S; Bay JO;
J Geriatr Oncol; 2015 Sep; 6(5):346-52. PubMed ID: 26116168
[TBL] [Abstract][Full Text] [Related]
33. Exploring health-related quality of life among non-Hodgkin's lymphoma survivors after completion of primary treatment: a cross-sectional study in Thailand.
Lekdamrongkul P; Pongthavornkamol K; Molassiotis A; Sriyuktasuth A; Siritanaratkul N; Chansatitporn N
Support Care Cancer; 2021 Nov; 29(11):6511-6522. PubMed ID: 33909148
[TBL] [Abstract][Full Text] [Related]
34. [Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
Wójcik B; Kowalczyk JR; Chybicka A; Wachowiak J; Drabko K; Zaucha-Prazmo A; Choma M; Gorczyńska E; Toporski J; Turkiewicz D; Kałwak K; Pieczonka A; Boruczkowski D
Przegl Lek; 2004; 61 Suppl 2():53-6. PubMed ID: 15686047
[TBL] [Abstract][Full Text] [Related]
35. Quality of Life is Similar between Long-term Survivors of Indolent and Aggressive Non-Hodgkin Lymphoma.
Beaven AW; Samsa G; Zimmerman S; Smith SK
Cancer Invest; 2016 Jul; 34(6):279-85. PubMed ID: 27379565
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomised, double-blind, placebo-controlled trial.
Luce BR; Singer JW; Weschler JM; Buckner CD; Sheingold SH; Shannon-Dorcy K; Appelbaum FR; Nemunaitis J
Pharmacoeconomics; 1994 Jul; 6(1):42-8. PubMed ID: 10172083
[TBL] [Abstract][Full Text] [Related]
37. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.
Ruiz-Soto R; Sergent G; Gisselbrecht C; Larghero J; Ertault M; Hennequin C; Manson J; de Kerviler E; Briere J; Mounier N
Cancer; 2005 Dec; 104(12):2735-42. PubMed ID: 16284986
[TBL] [Abstract][Full Text] [Related]
38. What is the role of autologous transplant for lymphoma in the current era?
Stiff P
Hematology Am Soc Hematol Educ Program; 2015; 2015():74-81. PubMed ID: 26637704
[TBL] [Abstract][Full Text] [Related]
39. Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Ciochetto C; Botto B; Passera R; Bellò M; Benevolo G; Boccomini C; Castellino A; Chiappella A; Freilone R; Nicolosi M; Orsucci L; Pecoraro C; Pregno P; Bisi G; Vitolo U
Ann Hematol; 2018 Sep; 97(9):1619-1626. PubMed ID: 29663029
[TBL] [Abstract][Full Text] [Related]
40. High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era.
Blaker YN; Eide MB; Liestøl K; Lauritzsen GF; Kolstad A; Fosså A; Smeland EB; Holte H
Leuk Lymphoma; 2014 Oct; 55(10):2319-27. PubMed ID: 24432894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
